Castration-resistant prostate cancer (CRPC)
Prostate cancer that keeps growing even though testosterone has been reduced to castrate levels.
Defined by PSA or radiographic progression with testosterone <50 ng/dL. Mechanisms: AR amplification and mutations, AR-V7 splice variants, intratumoural androgen synthesis, glucocorticoid receptor bypass, lineage plasticity to neuroendocrine phenotype. Since 2026 the FDA label language 'androgen pathway modulation-naive or -sensitive' replaces 'hormone-sensitive'.
Pages like this
not linked directly; found by shared links- ProductEnzalutamide
Shares Androgen receptor pathway inhibitor (ARPI), Prostate Cancer Foundation (PCF), mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), Androgen receptor signalling.
- TrialLATITUDE
Shares Androgen receptor pathway inhibitor (ARPI), mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), Prostate cancer.
- ProductBicalutamide
Shares Androgen receptor pathway inhibitor (ARPI), Androgen receptor signalling, Prostate cancer.
- TargetAndrogen receptor
Shares AR-V7 splice variant, Androgen receptor pathway inhibitor (ARPI), Leuprolide (leuprorelin) and GnRH agonists, Prostate Cancer Foundation (PCF).
- ProductAbiraterone acetate
Shares Androgen receptor pathway inhibitor (ARPI), Prostate Cancer Foundation (PCF), mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), Androgen receptor signalling.
- IdeaDestroy the truncated androgen receptor that hormone drugs cannot touch
Shares Androgen receptor signalling, Acquired resistance to every therapy, Prostate cancer.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares PSMAddition, Prostate cancer.
- PathwayRNA splicing
Shares AR-V7 splice variant, Androgen receptor signalling, Prostate cancer.